Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Trial ID or NCT#

NCT00230282

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.

Official Title

A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - ≥ age 18 - Karnofsky performance status 60% or above - Confirmed immunohistological diagnosis of Chronic Lymphocytic Leukemia (CLL) - Rai Stage I to IV as follows: - Advanced stage disease (Rai Stage III or IV, or modified Rai High Risk) - OR - Patients with Rai Stage I - II or (Modified Rai Intermediate-Risk) disease must have an indication for therapy based on 1996 NCI revised criteria for active disease as follows: - Any one of the following disease-related symptoms: 1. Weight loss ≥ 10% body weight within the previous 6 months 2. Extreme fatigue 3. Fever greater than 100.5° F for ≥ 2 weeks without evidence of infection 4. Night sweats without evidence of infection - Evidence of progressive marrow failure based on the development of worsening of anemia or thrombocytopenia - Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid therapy - Massive (> 6 cm below the left costal margin) or progressive splenomegaly - Bulky (>10 cm in cluster) or progressive lymphadenopathy - Progressive lymphocytosis > 50% increase over 2 months, or anticipated doubling time < 6 months - Patients with immunoglobulin VH gene in unmutated nucleotide sequence configuration, as defined by ≥ 98% homology with the nearest germline counterpart - Serum creatinine ≤ 2x the upper limit of normal - Total serum bilirubin ≤ 2x the upper limit of normal. - AST ≤ 2x the upper limit of normal. - ALT ≤ 2x the upper limit of normal. - Signed written informed consent
Exclusion Criteria:
  1. - Prior pharmacological treatment for CLL - Past history of anaphylaxis following exposure to monoclonal antibodies - Active secondary malignancy or a history of malignant disease (other than CLL or non-melanoma skin cancer) within the preceding 5 years - Any medical condition requiring systemic corticosteroids - Active systemic infection - Major systemic or other illness (including Coombs positivity and active hemolysis) that would, in the opinion of the investigator, interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of study results - HIV positive by serologic testing - Pregnant or nursing female - Unwilling/unable to practice an acceptable form of contraception.
View All Criteria
Show Less

Investigator(s)

James L. Zehnder, M.D.
James L. Zehnder, M.D.
Hematologist, Pathologist
Professor of Pathology (Research) and of Medicine (Hematology)
Yasodha Natkunam, M.D., Ph.D
Yasodha Natkunam, M.D., Ph.D
Pathologist, Hematopathologist, Surgical pathologist, Immunodiagnosis pathologist
Ronald F. Dorfman, MBBch, FRCPath Professor of Hematopathology
Athena Cherry

Contact us to find out if this trial is right for you.

Contact

Nini Estevez
6507254041

View on ClinicalTrials.gov